news Reseachers develop first test to predict tumour radiation therapy sensitivity 23 July 2015 | By Victoria White Researchers have developed a test that analyses the sensitivity of tumours to radiation therapy and could lead the way for personalised therapies...
news Gene therapy gives long-term protection to photoreceptor cells in retinitis pigmentosa model 15 July 2015 | By Victoria White Scientists have shown that gene therapy can give protection to the light-sensitive photoreceptor cells responsible for colour vision in retinitis pigmentosa...
news Final agenda released for the Next Generation Sequencing USA Congress & co-located Single Cell Genomics and Transcriptomics USA Congress, 27-28 October 2015, Boston, USA 13 July 2015 | By Oxford Global With four months to go until the Next Generation Sequencing USA Congress and co-located Single Cell Genomics and Transcriptomics USA Congress, Oxford Global Conferences are delighted to announce the release of the final agenda...
news Epizyme and Celgene extend cancer therapy research collaboration 9 July 2015 | By Victoria White Epizyme has amended and restated its agreement with Celgene to extend their research collaboration for at least three additional years...
news Registration has now opened for Oxford Global’s Cell & Gene Therapy Congress 2015 8 July 2015 | By Oxford Global Oxford Global Conferences are proud to present the Cell & Gene Therapy with our co-located 2nd Annual Stem Cell Congress is taking place on the 9th & 10th of November in London, UK...
news Biogen and AGTC team up to develop gene therapies for ophthalmic diseases 2 July 2015 | By Victoria White Biogen and AGTC have announced a broad collaboration and license agreement to develop gene therapies for multiple ophthalmic diseases...
news Celgene and Juno Therapeutics announce 10 year immunotherapy collaboration 30 June 2015 | By Victoria White Celgene and Juno Therapeutics have entered into a global collaboration for the development and commercialisation of immunotherapies...
news Preclinical data on Neuralstem’s genetically modified HK532-IGF-1 stem cells in Alzheimer’s disease presented at ISSCR 26 June 2015 | By Victoria White Neuralstem has presented preclinical data on genetically modified HK532-IGF-1 stem cells in Alzheimer's disease at the ISSCR Annual Meeting...
news Lycera and Celgene collaborate to advance novel immune modulators 10 June 2015 | By Victoria White Lycera has formed of an exclusive global collaboration with Celgene to take forward Lycera's proprietary pipeline for cancer and immune-mediated diseases...
news Fibrocell and Intrexon announce positive preclinical data for FCX-007 in RDEB 9 June 2015 | By Victoria White Fibrocell and Intrexon have announced positive preclinical data for FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa...
news Amended Celgene and bluebird bio collaboration to focus on the development of anti-BCMA products 4 June 2015 | By Victoria White The existing global collaboration between Celgene and bluebird bio has been amended and restated to focus on developing product candidates targeting BCMA...
news Inovio partners with GeneOne Life Science for MERS vaccine clinical development 3 June 2015 | By Victoria White Inovio has said it will advance its DNA vaccine for MERS into a Phase I clinical trial in healthy volunteers in a collaboration with GeneOne Life Science...
news First cancer-promoting oncogenes discovered in choroid plexus carcinoma 21 May 2015 | By Victoria White Researchers have identified three genes that play a pivotal role in choroid plexus carcinoma, a discovery that could lead to more effective treatment...
news Genethon and Selecta Biosciences to research repeat dosing for gene therapies 13 May 2015 | By Victoria White Genethon and Selecta Biosciences have announced an ongoing research collaboration with the goal of enabling repeat dosing for gene therapies...
news Significant progress made towards individualised cancer immunotherapy 12 May 2015 | By Victoria White Mainz-based researchers have made significant advances with regard to the development of individualised cancer immunotherapy strategies...
